Bradanicline

From Wikipedia, the free encyclopedia
  (Redirected from TC-5619)
Jump to: navigation, search
Bradanicline
Bradanicline structure.svg
Identifiers
Synonyms TC-5619
CAS Number
PubChem CID
UNII
KEGG
ChEMBL
Chemical and physical data
Formula C22H23N3O2
Molar mass 361.437 g/mol
3D model (Jmol)
  (verify)

Bradanicline (INN,[1] code name TC-5619) is a drug which was being developed by Targacept that acts as a partial agonist at the α7 subtype of the neural nicotinic acetylcholine receptors. It showed cognitive enhancing effects in animal studies, and was being developed through a collaboration between Targacept and AstraZeneca as a potential treatment for schizophrenia and attention deficit disorder. [2] Phase I clinical trials were completed successfully, and it was in phase II trials.[3]

In May 2011, AstraZeneca declined to exercise its right to license the compound.[4] In September 2012, Targacept ended its development of badanicline for the purpose of treating ADHD in adults.[5] It was being studied for cognitive and memory enhancement.[6]

Bradanicline was discontinued for Alzheimer's disease and cognitive impairment in schizophrenia in late 2013.[7] It was also discontinued for ADHD, and no longer seems to be being developed.[7]

References[edit]